Regadenoson myocardial perfusion scintigraphy for the evaluation of coronary artery disease in patients with lung disease: A series of five cases
File(s)
Author(s)
Reyes, Eliana
Underwood, Stephen Richard
Type
Journal Article
Abstract
Coronary artery disease (CAD) is a leading cause of death and morbidity globally. Myocardial perfusion scintigraphy (MPS) is commonly used for the diagnosis of CAD, necessitating hyperaemia achieved either by physical exertion or by pharmacological stress, most commonly through use of a coronary arteriolar dilator. This is challenging in patients with respiratory conditions because exercise may be submaximal and adenosine is contraindicated because of the risk of bronchoconstriction. Regadenoson is the only selective adenosine A2A receptor agonist approved as a vasodilator in MPS. The risk of bronchospasm with regadenoson has been investigated in large, randomised trials; however, patients with the most severe respiratory conditions were not included. In this case series, we present the use of regadenoson MPS in five patients with moderate-to-severe lung conditions, including patients requiring lung volume reduction surgery and lung transplant. In all cases, regadenoson MPS provided valuable information for risk assessment and treatment optimisation. Although dyspnoea occurred in all patients, regadenoson was well tolerated without serious adverse events or bronchospasm; in no case was intervention required to treat dyspnoea.
Date Issued
2020
Date Acceptance
2019-10-15
Citation
Journal of Nuclear Cardiology, 2020, 27, pp.315-321
ISSN
1071-3581
Publisher
Springer Verlag
Start Page
315
End Page
321
Journal / Book Title
Journal of Nuclear Cardiology
Volume
27
Copyright Statement
© 2019 The Author(s). This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://creativ
ecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and
indicate if changes were made.
Commons Attribution 4.0 International License (http://creativ
ecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and
indicate if changes were made.
Sponsor
CV Therapeutics Inc
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000500351400005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Grant Number
CVT 5132
Subjects
Science & Technology
Life Sciences & Biomedicine
Cardiac & Cardiovascular Systems
Radiology, Nuclear Medicine & Medical Imaging
Cardiovascular System & Cardiology
Regadenoson
myocardial perfusion scintigraphy (MPS)
coronary artery disease (CAD)
lung disease
vasodilators
OBSTRUCTIVE PULMONARY-DISEASE
DOUBLE-BLIND
A(2A) AGONIST
ADENOSINE
SAFETY
ASTHMA
STRESS
TRIAL
Publication Status
Published
Date Publish Online
2019-12-03